This review aims to summarise the physiology of C-reactive protein (CRP), its possible roles and limitations as an inflammatory and infective marker in intensive care medicine, and also the emerging roles of CRP in the pathogenesis of cardiovascular and autoimmune diseases. Observational and animal studies on uses of CRP were retrieved from the PubMed database without any language restrictions. Quantitative data were not pooled because of the heterogeneity of patient characteristics and disparate ways in which CRP was studied. Serum CRP concentrations are determined by the synthetic rate of its production in the liver regulated predominantly by interleukin-6. It has a half-life of 19 hours and is relatively slow in its onset and offset in response to an acute inflammatory process when compared to procalcitonin. It has some favourable properties and limitations as an inflammatory marker. An elevated CRP concentration is not specific to infections and the absolute CRP concentrations cannot be used to differentiate between bacterial, fungal and severe viral infections. The dynamic response of CRP to therapy that aims to modify the underlying inflammatory process and the clinical context of a patient are of pivotal importance when CRP concentrations are interpreted. CRP is found to be a significant partaker and prognostic factor in a wide range of cardiovascular and chronic diseases. In summary, CRP concentration is an important prognostic factor of many acute and chronic diseases. Serial CRP measurements may be useful to reflect a patient's response to therapy that aims to modify the underlying inflammatory process.
C-reactive protein (CRP) was first discovered in 1930 when a protein in the serum of patients with Streptococcus pneumoniae was found to precipitate and bind to the C-polysaccharide derived from the pneumococcal cell wall 1 . It has been known for a long time that CRP is one of many non-specific acute phase reactants that are elevated during an inflammatory process. Because the CRP response to an inflammatory process is non-specific, many clinicians have not adopted its use as a predictive and prognostic test in intensive care medicine. Furthermore, the role of CRP as a predictor of infection, instead of inflammation, has become even more controversial since the introduction of procalcitonin as a test in this regard. Comparing CRP with other inflammatory markers such as procalcitonin can be difficult because of their different kinetics and many studies have looked at different types of patients 2 . The overall evidence suggests that procalcitonin has much faster kinetics, both in its onset and offset, and may also be more specific than the CRP in diagnosing some infections [3] [4] [5] . Because the CRP test is widely available and relatively cheap, it is likely to be widely used in many institutions in the foreseeable future. It is not the intention of this brief review to compare the advantages and disadvantages of CRP with the procalcitonin because this subject has been adequately reviewed 3, 6 , but to summarise our current knowledge on CRP as a marker of inflammation and partaker in diseases that are relevant to the practice of intensivists.
This review aims to summarise the physiology of CRP, its potential roles and limitations as an inflammatory marker in intensive care medicine, and its emerging roles in the pathogenesis of some cardiovascular and autoimmune diseases. During the literature search for relevant articles in PubMed database before September 10, 2008, the following search terms, "C-reactive protein", "critically ill", "infection", "organ failure", "bacteraemia", "fungaemia", "sepsis", "cardiovascular disease" and "thromboembolism" were used without any language restrictions. Relevant references from the articles identified from the literature search were also retrieved for further analysis. Quantitative data of the studies were not pooled by meta-analytic techniques in this review because of the heterogeneity of patient characteristics and the disparate ways CRP were studied in the identified studies.
PHySIoLoGy oF C-REACTIVE PRoTEIN
The gene for CRP is on chromosome 1 and about 35 to 40% of the variability of baseline CRP concentrations between different healthy individuals is controlled by genetic polymorphisms in the CRP gene 7, 8 . Plasma CRP is predominantly produced by the hepatocytes and regulated by cytokine interleukin-6 (IL-6), and to a much lesser extent also by IL-1β and tumour necrosis factor-α 9 , although extra-hepatic synthesis of CRP has also been reported in neurons, atherosclerosis plaques, monocytes and lymphocytes 10 . The liver is also the only significant site through which CRP is cleared at a constant rate from the plasma. As such, the plasma CRP concentrations are almost solely determined by the synthetic rate of its production in the liver and its plasma half-life is about 19 hours 11 .
The median serum CRP concentration in healthy individuals is about 0.8 mg/l 12 . Serum CRP concentrations have no diurnal variation and are not affected by eating or age 13, 14 . Apart from fulminant liver failure, there are no other pathologies and very few drugs (e.g. statins, niacin, fibrates) that will reduce the CRP concentrations, unless they also affect the underlying acute-phase stimulus such as antibiotics for infection or corticosteroids for an inflammatory disease 11 . on the other hand, obesity, smoking, diabetes mellitus, lack of exercise and hormonal therapy (oestrogens or progesterones) are associated with a mildly elevated CRP concentration 15 .
C-REACTIVE PRoTEIN AS A MARKER oF INFLAMMATIoN
CRP is one of many acute phase reactants associated with an inflammatory process. It has to be emphasised that a high CRP concentration is not specific to infections. The inflammatory conditions that have been described to be associated with a high CRP concentration may include infections such as bacterial infections 16 , fungal infections 17 and severe viral infections including severe acute respiratory syndrome 18 , systemic inflammatory diseases such as rheumatoid arthritis 19, 20 , tissue necrosis such as myocardial infarction 16, 21 and necrotising pancreatitis 22 , multiple trauma 23 , neoplasia 24, 25 , vasculitis or serositis during the flare-ups of systemic lupus erythematosus (SLE) 26 and possibly in some drug overdoses 27 (Table 1 ). There are, however, a few exceptional inflammatory conditions that are associated with a very mild or even absent response in CRP (<10 to 20 mg/l), such as scleroderma, dermatomyositis and ulcerative colitis 11, 20 .
Although CRP is only a non-specific marker of inflammation, it has some favourable properties and potential uses in critically ill patients. First, although CRP is produced by the liver and may be significantly reduced in acute fulminant liver failure 28 , recent evidence suggests that CRP response to infections still remains normal in patients with cirrhosis 29 . Second, age and nutritional status of the patient have no effect on the CRP response to sepsis 14, 30 . Third, although an elevated CRP concentration is associated with many inflammatory diseases, an extremely high concentration of CRP (e.g. >200 mg/l) appears to be very unusual in conditions other than severe infections (Table 1) [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . For example, although multiple trauma is often associated with a sustained elevation of CRP concentrations over a period of four to seven days 23 , a progressive increase in CRP over 200 mg/l is very unusual in the absence of infective complications, especially if it occurs later than three days after the onset of trauma 45 . Similarly, some concurrent acute diseases, such as neutropenia and graft-versus-host disease, also do not affect the CRP response to active infection 34, 46 . Furthermore, studies showed that a sudden rise in daily CRP concentrations can be useful as an early warning sign of nosocomial infections in critically ill patients 47, 48 , and as such, it may alert clinicians to initiate investigations such as microbiological cultures, radiological imaging or empirical antimicrobial therapy 3 . Fourth, inflammatory response to an infection is expected to subside within 48 to 72 hours after the initiation of appropriate antimicrobial therapy. Studies have shown that a failure of the CRP concentrations to reduce after 48 hours of initiation of antimicrobial therapy may signify either inadequate or inappropriate therapy 49, 50 and thus, CRP may also act as a warning sign that the treatment plan or antimicrobial therapy is not working and needs to be revised. Finally, a persistently elevated CRP concentration during the recovery phase of a critical illness may signify the presence of persistent inflammation or new nosocomial sepsis after the critical illness and is associated with an increased risk of intensive care readmission and unexpected mortality after intensive care unit (ICU) discharge during the same hospitalisation [51] [52] [53] . CRP may also be useful as a prognostic marker for risk stratification before ICU or hospital discharge after a critical illness 38, 53 . Some other possible uses of serum CRP concentrations as a marker of inflammation in critically ill patients are further described in Table 2 [45] [46] [47] [48] [49] [50] [54] [55] [56] . CRP has significant limitations as a marker of inflammation in critically ill patients. First, CRP has a relatively long half-life (19 hours). CRP concentration may be relatively low or normal at the beginning of an inflammatory process or infection and for the same reason, it may remain significantly elevated during the initial recovery phase of an inflammatory process. Therefore, the dynamic response of the CRP concentrations to treatment over a period of days is much more useful than a single value 2, 3, 48, 49 . Second, CRP concentrations should be interpreted with the possible confounders in mind 3 . For example, although CRP is useful in predicting infections in patients with cirrhosis, its use in patients with acute fulminant liver failure is very limited 28 . Use of corticosteroids is another factor that may reduce CRP response to infection 11 . on the other hand, some haematological therapies, such as interleukin-2 treatment and donor granulocyte transfusions, can induce a significant rise in CRP (>150 mg/l) in the absence of infection 57 . Third, the absolute value of CRP is not sensitive or specific enough to discriminate between bacterial, fungal or severe viral infections [16] [17] [18] . Likewise, CRP is not sensitive enough to differentiate between infections from gram-positive and gram-negative organisms 58 . Fourth, like many clinical investigations in medicine, the utility of CRP can only be as good as the clinician using it when the results are interpreted with the clinical context. It is important to understand that the probability of a disease as predicted by a diagnostic test (post-test probability) is determined by both the probability of the disease before the test (pre-test probability) and performance of the diagnostic test 59 . The clinical condition of the patient, timing of the CRP test in relation to the onset of the disease or initiation of anti-inflammatory (or antimicrobial) therapy, and the recent CRP results are all important determinants of the pre-test probability of an ongoing or increasing inflammation Area under the receiver operating characteristic curve for the CRP concentrations to diagnose bacteraemia =0.79-0.85.
Diagnosis of acute necrotising pancreatitis 22
CRP >150 mg/l within 48 hours of onset of symptoms indicated necrotising pancreatitis (sensitivity and specificity >80%).
3. As one of the six components of IPS: (CRP, temperature, heart rate, respiratory rate, white cell counts, Sequential organ Failure Assessment score) 48 or guide obtain culture sampling and empirical prescription of antibiotics 3, 47 CRP >60 mg/l is assigned with a score of 6 and an IPS score <14 implies infection is unlikely (<14%). A maximum daily CRP variation above 41 mg/l from the previous day's level plus an absolute concentration above 87 mg/l was associated with an 88% risk for ICU-acquired infection.
4. As a trend monitor to predict response to antibiotics 49, 50 An increase in CRP >22 mg/l in the first 48 hours after antibiotics signifies ineffective antibiotic therapy (77% sensitivity, 67% specificity).
5.
As a marker to stratify risks before ICU discharge 52, 53 CRP >100 mg/l on the day of ICU discharge was associated with an increased risk of readmission and unexpected death after ICU discharge.
Exclusion of infective endocarditis 54
CRP<10 mg/l has an 87.5% negative predictive value to exclude infective endocarditis.
7. As part of an ICU admission blood test prognostic score (alanine aminotransferase, CRP, cholesterol, creatinine kinase myocardial band, leucocytes, potassium, platelet counts, triglycerides and age) 55 Area under the receiver operating characteristic curve of the model = 0.853 (odds ratio 1.44 per categorical increment from <11, 11-50, 50-100,100-150, >150 mg/l).
8. Prediction of liver failure after extensive liver resection 56 CRP<32 mg/l on postoperative day 1 predicts liver failure after liver resection.
Suspicion of sepsis in patients with trauma 45
Progressive increases in CRP >200 mg/l three days after the onset of trauma.
CRP=C-reactive protein, IPS=Infection Probability Score, ICU=intensive care unit. 2. Response is not specific to the process of inflammation 11 3. Not useful to differentiate between bacterial, fungal, and severe viral infections or between gram-positive and gramnegative infections [16] [17] [18] 58 4. Not useful in patients with acute fulminant liver failure 28 5. Can be significantly reduced with high dose systemic corticosteroids 11 6. Can be significantly increased with interleukin-2 treatment and donor granulocyte transfusions 57 7. No randomised controlled trial data to support its role in improving patient-centred outcomes and hence the appropriate interpretation of the CRP results. Finally, no randomised controlled trials have demonstrated that a single or serial use of CRP can improve patient-centred outcomes. The limitations of CRP as a marker of inflammation in critically ill patients are summarised in Table 3 .
C-REACTIVE PRoTEIN AS A PARTAKER IN THE IMMUNE SySTEM AND CARDIoVASCULAR DISEASES
It is now known that CRP is not only a bystander or marker of inflammatory diseases, but it is also a partaker in the host immune response to infection, pathogenesis of cardiovascular diseases and prevention of autoimmunity. Human CRP consists of five identical protomers and each of these has a binding site for the many intrinsic and extrinsic ligands 9 . CRP has the highest affinity to phosphocholine residues, but it can also bind to phosphoethanolamine, chromatin, histones, fibronectin, laminin and polycations 9 . The intrinsic ligands that bind to the CRP include oxidised low-density lipoprotein (LDL) and damaged cell membranes in cell necrosis or apoptosis 60 . The extrinsic ligands that bind to CRP include glycan, phospholipid and other components of bacteria, fungi and parasites 60 . For example, Streptococcus pneumoniae and Haemophilus influenzae have a particularly large quantity of phosphocholine on their cell wall surfaces. After binding to these intrinsic or extrinsic ligands, CRP will trigger further pro-inflammatory and anti-inflammatory activities leading to a successful immune response to clear the infections and cell debris.
It is likely that the overall pro-inflammatory or anti-inflammatory effect of CRP will change, depending on the circumstances 9 . The proinflammatory activities of CRP include activation of early part of complement cascade (C1 to C4), enhancing phagocytosis by binding to the immunoglobulins and apoptotic cells, up-regulation of the expression of adhesion molecules in the endothelial cells, and an increase in release of IL-1, IL-6, IL-8, IL-18, and tumour necrosis factor-α leading to an amplification loop of systemic inflammation 61 . The anti-inflammatory activities of CRP include induction of expression of IL-1 receptor antagonist, an increase in the release of anti-inflammatory IL-10, suppression of the release of interferon-γ, and interaction with factor H leading to limitations in activation of the late stage complement cascade (C5 to C9). It appears that there is a balance through which CRP is capable of acting as an opsonin in the host response to infection, but at the same time, limiting excessive damaging inflammatory response to the host 9 .
Apart from being involved in host response to infections, CRP plays an important role in clearing debris from cell necrosis or apoptosis. Although phosphocholine residues are abundant in the outer leaflets of most human biological membranes, CRP cannot bind to these phosphocholine residues when they are embedded inside a viable human cell membrane. CRP is, however, capable of binding to the phosphocholine residues once they are converted to lyso-phosphocholine during apoptosis or necrosis leading to phagocytosis and clearance of the cell debris. In fact, CRP and complement activation is consistently being found in cell necrosis 62, 63 . It has also been postulated that a failure to clear cell debris may contribute to the pathogenesis of some autoimmune diseases such as systemic lupus erythematosus 61 . For example, anti-CRP antibodies are found in up to 78% of systemic lupus erythematosus patients and induction of human CRP gene in animals can significantly delay the development of the disease 61, 64 .
CRP plays a role in clearing oxidised lipoproteins in addition to host defence and clearing cell debris. CRP does not bind to normal native LDL, but it has a strong affinity to the oxidised LDL or very lowdensity lipoprotein. After binding to the oxidised lipoproteins, CRP may trigger a variety of actions through its interactions with endothelial cells and vascular smooth muscle. These actions include down-regulation of nitric oxide synthetase, release of endothelin-1, IL-6 and plasminogen activator inhibitor, up-regulation of adhesion molecules and chemokines that facilitate leucocyte migration, and stimulation of vascular smooth muscle migration and proliferation [65] [66] [67] . Many of these mechanisms are now believed to be contributing to the pathogenesis, progression and complications of atheroma. These experimental findings were further supported by strong observational data that a high CRP concentration is indeed a very strong independent risk factor in predicting cardiovascular events, more than some other traditional cardiovascular risk factors such as LDL cholesterol concentration 66 . Using high-sensitivity CRP assays, individuals with a CRP concentration >2.4 mg/l are associated with twice the risk of having a coronary event as those with a CRP concentration <1 mg/l 11 , and CRP concentrations <1, 1 to 3, and >3 mg/l can be used to stratify cardiovascular risk as low, intermediate and high, respectively 66 . The emerging evidence also suggests that many cardiovascular treatments, including aspirin and statins, are in fact more effective in patients with an elevated CRP concentration 66 . The possible role of inflammation and CRP in some chronic illnesses are summarised in Table 4 66, [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] .
In summary, CRP is increasingly being recognised as an important partaker and prognostic marker in many cardiovascular and auto-immune diseases. CRP is a non-specific marker of inflammation and has some favourable properties and limitations. The dynamic response of CRP to therapy that aims to modify the inflammatory process and the clinical context of a patient are of pivotal importance when CRP concentrations are interpreted. Finally, as a marker of infection CRP has poor specificity but some sensitivity. 
